Business Context and Reporting Period
This Form 8-K is filed by Digital Ally, Inc. (trading symbol: DGLY) on March 14, 2024. The filing addresses a notice received from the Nasdaq Listing Qualifications staff regarding the company's compliance with corporate governance standards. Note: The request metadata references "KUSTOM ENTERTAINMENT, INC.", but the filing text explicitly identifies the registrant as Digital Ally, Inc.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The material change reported is the resignation of Mr. Michael J. Caulfield from the Board of Directors, effective January 31, 2024. This resignation resulted in the company failing to meet Nasdaq Listing Rule 5605 requirements, specifically:
- The Audit Committee no longer has at least three independent directors.
- The Compensation Committee no longer has at least two independent directors.
Outlook, Risks, and Management Commentary
Management Action: Management has resolved to take commercially reasonable steps to fill the Board vacancy with a new independent director as soon as practical. They anticipate regaining compliance within the Cure Period.
Cure Period: The company has until the earlier of its next annual shareholders' meeting (or July 29, 2024, if the meeting is held before that date) or January 31, 2025, to regain compliance.
Risks and Contingencies:
- If compliance is not achieved by the end of the Cure Period, Nasdaq will issue a written notice of delisting.
- There is no assurance the company will satisfy Listing Rule 5605 or other listing criteria.
- Forward-looking statements regarding future compliance involve risks and uncertainties that may cause actual results to differ materially.
Investor Verification Checklist
- Verify the timeline for the next annual shareholders' meeting to determine the exact deadline for the Cure Period.
- Monitor subsequent filings for the appointment of a new independent director to the Board.
- Review the company's periodic reports (10-K/10-Q) for any additional governance or financial risks not detailed in this 8-K.
- Confirm the current status of the Audit and Compensation Committee compositions in future filings.